Drugs for the treatment of Parkinson's disease:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Berlin [u.a.]
Springer
1989
|
| Schriftenreihe: | Handbook of experimental pharmacology
88 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | Literaturangaben |
| Beschreibung: | XXIV, 599 S. Ill., graph. Darst. |
| ISBN: | 3540500413 0387500413 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV001779719 | ||
| 003 | DE-604 | ||
| 005 | 20140402 | ||
| 007 | t | ||
| 008 | 890804s1989 ad|| |||| 00||| eng d | ||
| 020 | |a 3540500413 |9 3-540-50041-3 | ||
| 020 | |a 0387500413 |9 0-387-50041-3 | ||
| 035 | |a (OCoLC)18557026 | ||
| 035 | |a (DE-599)BVBBV001779719 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-19 |a DE-12 |a DE-355 |a DE-29 |a DE-20 |a DE-188 |a DE-578 | ||
| 050 | 0 | |a QP905 | |
| 050 | 0 | |a RC382 | |
| 082 | 0 | |a 616.8/33061 |2 19 | |
| 082 | 0 | |a 615/.1 |2 19 | |
| 082 | 0 | |a 616.833061 | |
| 082 | 0 | |a 615.1 | |
| 084 | |a XI 1701 |0 (DE-625)152977:12907 |2 rvk | ||
| 084 | |a XI 5700 |0 (DE-625)153017:12905 |2 rvk | ||
| 084 | |a MED 604b |2 stub | ||
| 084 | |a QV 4 |2 nlm | ||
| 084 | |a MED 970b |2 stub | ||
| 245 | 1 | 0 | |a Drugs for the treatment of Parkinson's disease |c contributors R. D. G. Blair ... Ed. Donald B. Calne |
| 264 | 1 | |a Berlin [u.a.] |b Springer |c 1989 | |
| 300 | |a XXIV, 599 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Handbook of experimental pharmacology |v 88 | |
| 500 | |a Literaturangaben | ||
| 650 | 7 | |a Drug Therapy |2 cabt | |
| 650 | 7 | |a Paralysis |2 cabt | |
| 650 | 7 | |a Chemotherapy |2 cabt | |
| 650 | 4 | |a Antiparkinsoniens | |
| 650 | 7 | |a Farmacotherapie |2 gtt | |
| 650 | 4 | |a Parkinson, Maladie de - Chimiothérapie | |
| 650 | 7 | |a Ziekte van Parkinson |2 gtt | |
| 650 | 4 | |a Antiparkinson Agents |x therapeutic use | |
| 650 | 4 | |a Antiparkinsonian agents | |
| 650 | 4 | |a Parkinson Disease |x drug therapy | |
| 650 | 4 | |a Parkinson's disease |x Chemotherapy | |
| 650 | 0 | 7 | |a Pharmakologie |0 (DE-588)4045687-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Antiparkinsonmittel |0 (DE-588)4224119-4 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Parkinson-Krankheit |0 (DE-588)4044683-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmakotherapie |0 (DE-588)4076066-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Parkinsonismus |0 (DE-588)4173363-0 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Parkinsonismus |0 (DE-588)4173363-0 |D s |
| 689 | 0 | 1 | |a Pharmakotherapie |0 (DE-588)4076066-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Antiparkinsonmittel |0 (DE-588)4224119-4 |D s |
| 689 | 1 | |5 DE-604 | |
| 689 | 2 | 0 | |a Parkinson-Krankheit |0 (DE-588)4044683-9 |D s |
| 689 | 2 | 1 | |a Pharmakologie |0 (DE-588)4045687-0 |D s |
| 689 | 2 | |5 DE-604 | |
| 700 | 1 | |a Calne, Donald B. |d 1936- |e Sonstige |0 (DE-588)128984481 |4 oth | |
| 700 | 1 | |a Blair, R. D. G. |e Sonstige |4 oth | |
| 830 | 0 | |a Handbook of experimental pharmacology |v 88 |w (DE-604)BV002390716 |9 88 | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=001199523&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-001199523 | ||
Datensatz im Suchindex
| _version_ | 1804116272607133696 |
|---|---|
| adam_text | GTH-FOI H DRUGS FOR THE TREATMENT OF PARKINSON S DISEASE CONTRIBUTORS R.
D. G. BLAIR, D. B. CALNE, S. G. DIAMOND, S. FAHN, A. FINE, V. GLOVER, M.
GOLDSTEIN, G. GOPINATHAN, O. HORNYKIEWICZ, R. HOROWSKI, J. IRWIN, J.
JANKOVIC, K. JELLINGER, H. KAUFMANN, H. L. KLAWANS, A. E. LANG, J. W.
LANGSTON, P. A. LEWITT, A. N. LIEBERMAN, C. H. MARKHAM, W. R. W. MARTIN,
E. G. MCGEER, P. L. MCGEER, J. A.OBESO, J.D. PARKES, J. B. PENNEY, R. F.
PEPPARD, H. A. ROBERTSON, M. SANDIER, W. SCHULTZ, I. SHOULSON, S.M.
STAHL, I. SUCHY, C. M. TANNER, H. TERAVAINEN, J. K. TSUI, M. D. YAHR,
A.B. YOUNG EDITOR DONALD B. CALNE SPRINGER-VERLAG BERLIN HEIDELBERG NEW
YORK LONDON PARIS TOKYO HONG KONG CONTENTS CHAPTER 1 NEUROPHYSIOLOGY OF
BASAL GANGLIA W. SCHULTZ , 1 A. INTRODUCTION 1 B. ELECTROPHYSIOLOGY OF
CONNECTIONS 2 I. PERIPHERAL AND CEREBRAL INPUT TO BASAL GANGLIA 2 1.
STRIATUM 2 A. PERIPHERAL INPUT 2 B. CEREBRAL INPUT 3 2. NUCLEUS
SUBTHALAMICUS 4 3. SUBSTANTIA NIGRA 4 II. INTERNAL BASAL GANGLIA
CONNECTIONS 4 1. NIGROSTRIATAL DOPAMINE SYSTEM 5 A. SUBSTANTIA NIGRA 5
B. STRIATUM 5 2. STRIATOPALLIDAL . 6 3. STRIATONIGRAL 7 4. NUCLEUS
SUBTHALAMICUS 7 5. NUCLEUS TEGMENTI PEDUNCULOPONTINUS 8 III. OUTPUT OF
BASAL GANGLIA . . . 8 1. PALLIDOTHALAMIC . . 8 2. NIGROTHALAMIC . 9
3. PALLIDOHABENULAR 9 4. NIGROCOLLICULAR 9 5. NUCLEUS TEGMENTI
PEDUNCULOPONTINUS 10 C. MOTOR CONTROL FUNCTIONS 10 I. ANATOMIC
CONSIDERATIONS 10 II. LESIONS, COOLING, AND LOCAL DRUG INJECTIONS 11 1.
STRIATUM 11 2. GLOBUS PALLIDUS 11 3. SUBSTANTIA NIGRA PARS RETICULATA 12
4. NUCLEUS SUBTHALAMICUS 12 III. NEURONAL RECORDINGS 13 1. STRIATUM 13
2. GLOBUS PALLIDUS 14 3-. SUBSTANTIA NIGRA PARS RETICULATA 15 XII
CONTENTS 4. NUCLEUS SUBTHALAMICUS 15 D. HIGHER FUNCTIONS 16 I. ANATOMY
OF CONNECTIONS 16 1. CORTICAL INPUT . 16 2. LIMBIC INPUT 16 3. OUTPUT 17
II. NEUROPSYCHOLOGIC DEFICITS AFTER LESIONS 17 III. NEURONAL RECORDINGS
18 1. UNTRAINED BEHAVIOR 18 2. CONTEXT-DEPENDENT RESPONSES TO DIRECTLY
TRIGGERING STIMULI 18 3. PREPARATION TO ACT . 20 A. NONDISCRIMINATIVE
INSTRUCTIONS 21 B. DISCRIMINATIVE INSTRUCTIONS 21 C. DELAYED RESPONSE
TASKS 22 D. SELF-INITIATED ACTS 23 E. DOPAMINERGIC FUNCTIONS 24 I.
ANIMAL MODELS OF PARKINSONISM . 24 1. MONKEY - . . 24 2. RODENT 25 II.
IMPULSE ACTIVITY OF DOPAMINE NEURONS 26 1. PERIPHERAL INPUT UNDER
ANESTHESIA 26 2. RELATIONS TO BEHAVIOR 27 A. EXECUTION OF MOVEMENTS 27
B. RESPONSES TO STIMULI 27 C. PREPARATION TO ACT 28 3. COMPARISON WITH
DEFICITS 29 F. CONCLUSIONS 30 I. FUNCTIONAL CONNECTIVITY 30 1.
LATERALIZATION OF FUNCTION 30 2. DISINHIBITION OF TARGET STRUCTURES 30
3. THE EXTRAPYRAMIDAL MOTOR SYSTEM . . . . . . . . 31 II. DOPAMINE
SYSTEM ** * 31 1. MISMATCH BETWEEN NEGATIVE AND POSITIVE IMAGE . . . .
31 2. PARADOXICAL KINESIA 31 3. NEURONAL ACTIVITY IN TARGET AREAS OF DA
NEURONS . . . . 32 III. CORTICOSTRIATAL ACTIVITY 32 REFERENCES 33
CHAPTER 2 PATHOLOGY OF PARKINSON S SYNDROME K.JELLINGER. WITH 9 FIGURES
47 A. INTRODUCTION 47 B. CYTOSKELETAL PATHOLOGY 49 I. LEWY BODIES 49 II.
HIRANO BODIES 51 CONTENTS XIII III. INTRACYTOPLASMIC EOSINOPHILIC
GRANULES 51 IV. MARINESCO BODIES 51 V. NEUROFIBRILLARY TANGLES 51 1.
ALZHEIMER S NEUROFIBRILLARY TANGLES 51 2. TANGLES IN PROGRESSIVE
SUPRANUCLEAR PALSY 52 VI. GRANULOVACUOLAR DEGENERATION 52 VII. AXONAL
DYSTROPHY AND GRUMELOUS DEGENERATION 53 VIII. NEURITIC PLAQUES AND
AMYLOID . 53 C. MAJOR TYPES OF PARKINSONISM 53 I. PARKINSON S DISEASE 54
II. PARKINSON S DISEASE AND ALZHEIMER S DISEASE 59 III. DIFFUSE LEWY
BODY DISEASE 62 IV. MULTISYSTEM DEGENERATIONS 63 V. PARKINSON-DEMENTIA
COMPLEX . 63 VI. PROGRESSIVE SUPRANUCLEAR PALSY 64 VII.
POSTENCEPHALITIC PARKINSONISM 64 VIII. VASCULAR OR MULTI-INFARCT
PARKINSONISM 66 IX. TOXIC PARKINSONISM 66 X. SYMPTOMATIC PARKINSONISM 67
D. MORPHOLOGICAL CORRELATES OF PATHOBIOCHEMISTRY 67 I. DOPAMINERGIC
SYSTEM 67 1. SUBSTANTIA NIGRA AND VENTRAL TEGMENTAL AREA 68 2.
STRIATOPALLIDUM AND OTHER CNS AREAS . 71 II. NORADRENERGIC SYSTEM 72 1.
LOCUS CERULEUS 72 2. DORSAL VAGAL NUCLEUS 75 III. SEROTONERGIC SYSTEM 75
IV. CHOLINERGIC SYSTEMS . 77 1. NUCLEUS BASALIS OF MEYNERT 77 2. NUCLEUS
TEGMENTI PEDUNCULOPANTINUS 80 3. WESTPHAL-EDINGER NUCLEUS ,. 81 V.
PEPTIDERGIC SYSTEMS . 81 E. MORPHOLOGICAL EFFECTS OF LEVODOPA TREATMENT
82 F. PATHOLOGY OF DEMENTIA IN PARKINSON S DISEASE 82 G. CONCLUDING
REMARKS 91 REFERENCES 94 CHAPTER 3 BIOCHEMICAL NEUROANATOMY OF THE BASAL
GANGLIA E.G. MCGEER AND P.L. MCGEER. WITH 12 FIGURES 113 A. INTRODUCTION
113 B. NEUROTRANSMITTERS IN THE EXTRAPYRAMIDAL SYSTEM 114 I. TYPE I:
AMINO ACID NEUROTRANSMITTERS 114 II. TYPE II: AMINE NEUROTRANSMITTERS
116 III. TYPE III: PEPTIDE NEUROTRANSMITTERS 118 XIV CONTENTS IV.
RECEPTOR SUBTYPES . 120 C. HETEROGENEITIES IN EXTRAPYRAMIDAL NUCLEI 121
I. MOSAICS OR GRADIENTS . 121 II. DIFFERENCES BETWEEN CAUDATE, PUTAMEN,
AND NUCLEUS ACCUMBENS 123 D. INTERCONNECTIONS IN THE EXTRAPYRAMIDAL
SYSTEM 124 E. SOME HYPOTHESES AS TO THE ROLE OF VARIOUS TRACTS IN THE
EXTRAPYRAMIDAL SYSTEM 128 F. CONCLUSIONS 130 G. APPENDIX: AFFERENTS AND
EFFERENTS OF EXTRAPYRAMIDAL NUCLEI . . . 130 REFERENCES 137 CHAPTER 4
RECEPTORS IN THE BASAL GANGLIA A.B. YOUNG AND J.B. PENNEY. WITH 2
FIGURES 149 A. INTRODUCTION 149 B. NEUROTRANSMITTER RECEPTOR PROPERTIES
149 C. DOPAMINE RECEPTORS 150 I. PROPERTIES AND SUBTYPES 150 II.
DISTRIBUTION 152 III. DOPAMINE RECEPTORS IN PARKINSON S DISEASE 155 IV.
IN VIVO STUDIES .156 D. GABA RECEPTORS 156 E. ACETYLCHOLINE RECEPTORS .
. . 1 5 6 F. OPIATE RECEPTORS 157 G. OTHER RECEPTORS 158 H. SUMMARY 158
REFERENCES . . . . . 159 CHAPTER 5 IMAGING THE BASAL GANGLIA W.R.W.
MARTIN. WITH 3 FIGURES 165 A. INTRODUCTION 165 B. STRUCTURAL IMAGING
TECHNIQUES 166 I. METHODOLOGY 166 1. X-RAY COMPUTED TOMOGRAPHY (CT) .
166 2. MAGNETIC RESONANCE IMAGING (MRI) 166 II. PARKINSON S DISEASE 166
III. HUNTINGTON S DISEASE 167 IV. DYSTONIA 167 V. OTHER MOVEMENT
DISORDERS 168 C. FUNCTIONAL IMAGING TECHNIQUES 168 I. METHODOLOGY 168 1.
POSITRON EMISSION TOMOGRAPHY (PET) 168 CONTENTS XV A. CEREBRAL BLOOD
FLOW AND METABOLISM 168 B. PRESYRIAPTIC DOPAMINERGIC FUNCTION 169 C.
DOPAMINE RECEPTORS 171 2. SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY
(SPECT) . 172 II. PARKINSON S DISEASE . 172 III. HUNTINGTON S DISEASE
174 IV. DYSTONIA 177 D. CONCLUSIONS 178 REFERENCES 178 CHAPTER 6 THE
NEUROCHEMICAL BASIS OF THE PHARMACOLOGY OF PARKINSON S DISEASE
0.HORNYKIEWICZ. WITH 4 FIGURES 185 A. INTRODUCTION 185 B. THE BASIC
NEUROCHEMICAL PATHOLOGY OF PARKINSON S DISEASE . . .185 I. THE
NIGROSTRIATAL DOPAMINE NEURON SYSTEM 186 II. EXTRASTRIATAL DOPAMINE
NEURONS 187 III. NONDOPAMINE NEURON SYSTEMS 188 C. PATHOPHYSIOLOGIC AND
PHARMACOLOGIC SIGNIFICANCE OF THE BIOCHEMICAL BRAIN ABNORMALITIES IN
PARKINSON S DISEASE . . . .189 I. NIGROSTRIATAL DOPAMINE LOSS 189 II.
EXTRASTRIATAL DOPAMINE CHANGES 190 III. NONDOPAMINE CHANGES 190 1.
CHANGES IN THE BASAL GANGLIA 190 A. NOREPINEPHRINE .* * * 191 B.
ACETYLCHOLINE 192 C. Y-AMINOBUTYRIC ACID . 192 D. SEROTONIN,
NEUROPEPTIDES 193 2. CHANGES OUTSIDE THE BASAL GANGLIA , . 193 D.
STRIATAL DOPAMINE DEFICIENCY AND THE PHARMACOTHERAPY OF PARKINSON S
DISEASE: SPECIAL ASPECTS OF DOPAMINE SUBSTITUTION . . 194 I.
COMPENSATORY CHANGES IN THE NIGROSTRIATAL DOPAMINE NEURONS 194 II.
COMPENSATED AND DECOMPENSATED STAGES OF PARKINSON S DISEASE AND THE GOAL
OF DOPAMINE SUBSTITUTION 195 III. THE ROLE OF THE COMPENSATORY CHANGES
FOR DOPAMINE SUBSTITUTION . 196 1. THE ROLE OF PRESYNAPTIC OVERACTIVITY
196 2. THE IMPORTANCE OF POSTSYNAPTIC SUPERSENSITIVITY FOR THE
PHARMACOLOGY OF PARKINSON S DISEASE 196 A. SPECIAL SENSITIVITY OF THE
PARKINSONIAN STRIATUM TO DOPAMINE SUBSTITUTION 197 B. REGIONAL
SELECTIVITY OF DOPAMINE SUBSTITUTION THERAPY . 197 C. NEW APPROACHES TO
DOPAMINE SUBSTITUTION 198 A. SELECTIVE DOPAMINE AUTORECEPTOR AGONISTS AS
A NEW CLASS OF SPECIFIC POTENTIAL ANTIPARKINSONIAN AGENTS . 198 XVI
CONTENTS P. AUTOGRAFTING OF DOPAMINE-PRODUCING CELLS INTO THE
PARKINSONIAN STRIATUM 198. E. PROSPECTS OF PREVENTIVE DRUG TREATMENT IN
PARKINSON S DISEASE . . 199 REFERENCES 199 CHAPTER 7 PYRIDINE TOXINS
J.W. LANGSTON AND I. IRWIN. WITH 3 FIGURES 205 A. INTRODUCTION 205 B.
WHAT ARE PYRIDINES? 205 I. HISTORICAL BACKGROUND 205 II. STRUCTURE AND
CHEMISTRY 205 III. BIOLOGIC ROLE 207 IV. DISTRIBUTION OF PYRIDINES 207
C. PYRIDINES AS TOXINS 208 I. HISTORY 208 II. ANIMAL MODELS 209 1.
INVERTEBRATES 209 2. AMPHIBIA 210 3. RODENTS 210 4. CAT 211 5. DOG 211
6. PRIMATES 212 D. FACTORS AFFECTING TOXICITY 212 I. MECHANISM OF ACTION
213 II. TOXICOKINETIC AND TOXICODYNAMIC EFFECTS 213 III. SPECIES
DIFFERENCES 214 IV. NEUROMELANIN . 215 V. AGE DIFFERENCES . ,. . . 216
E. PYRIDINES AS PROTECTORS? , . . . . . 217 F. TOXIC
TETRAHYDROPYRIDINES: A GROWING FAMILY * . . 218 G. PYRIDINES AND
PARKINSON S DISEASE 220 REFERENCES . . . . 220 CHAPTER 8 THE
RELATIONSHIP BETWEEN PARKINSON S DISEASE AND OTHER MOVEMENT DISORDERS
J.JANKOVIC. WITH 4 FIGURES. . . : 227 A. INTRODUCTION 227 B. SECONDARY
PARKINSONISM . 232 I. DRUG-INDUCED PARKINSONISM 232 II. TOXIN-INDUCED
PARKINSONISM 233 1. MANGANESE 233 2. CARBON MONOXIDE 234 CONTENTS XVII
3. CYANIDE 236 4. CARBON DISULFIDE 236 5. OTHER TOXINS 237 III.
METABOLIC CAUSES OF PARKINSONISM 238 1. HYPOPARATHYROIDISM 238 2.
ACQUIRED HEPATOCEREBRAL DEGENERATION 239 3. OTHER METABOLIC CAUSES 239
IV. POSTENCEPHALITIC PARKINSONISM AND SLOW VIRUS INFECTIONS . . 239 V.
VASCULAR PARKINSONISM 242 VI. BRAIN TUMORS 243 VII. TRAUMA 244 VIII.
HYDROCEPHALUS 245 IX. SYRINGOMESENCEPHALIA 246 C. SPORADIC MULTIPLE
SYSTEM DEGENERATIONS (PARKINSONISM-PLUS) . . 246 I. PROGRESSIVE
SUPRANUCLEAR PALSY 246 II. SHY-DRAGER SYNDROME 249 III.
OLIVOPONTOCEREBELLAR ATROPHIES 250 IV. CORTICOBASAL DEGENERATION . 252
V. PARKINSONISM-DEMENTIA-ALS COMPLEX 252 VI. STRIATONIGRAL DEGENERATION
254 D. INHERITED MULTIPLE SYSTEM DEGENERATIONS 256 I. HUNTINGTON S
DISEASE 256 II. WILSON S DISEASE 258 III. HALLERVORDEN-SPATZ DISEASE 258
IV. OTHER FAMILIAL PARKINSONIAN SYNDROMES 259 V. FAMILIAL BASAL GANGLIA
CALCIFICATIONS 259 VI. NEUROACANTHOCYTOSIS 259 REFERENCES 260 CHAPTER 9
EVALUATION OF PARKINSON S DISEASE H.TERAVAINEN, J.TSUI AND D.B.
CALNE. WITH 2 FIGURES . . . . . .271 A. INTRODUCTION 271 B. SUBJECTIVE
ASSESSMENT 271 C. OBJECTIVE ASSESSMENT 275 I. TREMOR ,275 II. RIGIDITY
276 III. HYPOKINESIA 277 D. SUMMARY 278 REFERENCES 278 CHAPTER 10
CLINICAL TRIALS FOR PARKINSON S DISEASE J.K.TSUI, H.TERAVAINEN AND D.B.
CALNE 281 XVIII CONTENTS A. INTRODUCTION 281 B. PHASES 281 C. DESIGN 282
D. RECRUITMENT 284 E. ASSESSMENT 284 F. STATISTICAL ANALYSIS 285 G.
CONCLUSIONS 286 REFERENCES 286 CHAPTER 11 EXPERIMENTAL THERAPEUTICS
DIRECTED AT THE PATHOGENESIS OF PARKINSON S DISEASE I. SHOULSON. WITH 1
FIGURE 289 A. INTRODUCTION 289 B. GENERAL STRATEGIES FOR PREVENTION AND
PROTECTION 289 C. ANTIOXIDATIVE PHARMACOTHERAPIES 290 D. CLINICAL TRIAL
OF DEPRENYL AND TOCOPHEROL ANTIOXIDATIVE THERAPY OF PARKINSONISM
(DATATOP) 293 I. PILOT STUDIES AND CANDIDATE DRUGS 293 II. FACTORIAL
DESIGN 295 III. MAJOR RESPONSE VARIABLE 295 IV. SAMPLE SIZE ESTIMATES
297 V. SYMPTOMATIC OR PROTECTIVE EFFECTS? 298 VI. RECRUITMENT 299 VII.
POTENTIAL PITFALLS 299 E. ANIMAL MODELS 300 F. NEURAL GRAFTING 301 G.
SUMMARY 301 REFERENCES * * * 302 V CHAPTER 12 ANTICHOLINERGIC DRUGS AND
AMANTADINE IN THE TREATMENT OF PARKINSON S DISEASE A. E. LANG AND R.D.G.
BLAIR 307 A. INTRODUCTION 307 B. ANTICHOLINERGICS 307 I. INTRODUCTION
307 II. MECHANISM OF ACTION 308 III. PHARMACOKINETICS 309 IV. CLINICAL
EFFECTS 309 V. SIDE EFFECTS 311 VI. CONCLUSIONS 312 C. AMANTADINE 312 I.
INTRODUCTION 312 CONTENTS XIX II. MECHANISM OF ACTION 313 III.
PHARMACOKINETICS 314 IV. CLINICAL EFFECTS 314 V. SIDE EFFECTS . . * 315
VI. CONCLUSIONS 317 REFERENCES 318 CHAPTER 13 THE PHARMACOLOGY OF
LEVODOPA IN TREATMENT OF PARKINSON S DISEASE: AN UPDATE P.A. LEWITT 325
A. INTRODUCTION , 325 B. THE EFFICACY OF LEVODOPA IN PARKINSONISM 326 I.
BACKGROUND 326 II. CLINICAL EFFECTIVENESS OF LEVODOPA IN PARKINSON S
DISEASE . . 328 III. USE OF LEVODOPA IN OTHER FORMS OF PARKINSONISM AND
OTHER MOVEMENT DISORDERS 330 IV. THERAPEUTIC PRINCIPLES FOR LEVODOPA 331
C. CLINICAL ASPECTS OF LEVODOPA PHARMACOKINETICS, PHARMACODYNAMICS, AND
METABOLISM 333 I. LEVODOPA PHARMACOKINETICS 333 II. LEVODOPA METABOLISM:
3-O-METHYLDOPA AND OTHER METABOLITES 337 III. OTHER METABOLIC EFFECTS OF
LEVODOPA 338 D. OTHER EFFECTS OF LEVODOPA 340 E. PHARMACODYNAMICS OF
LEVODOPA THERAPY 342 F. MECHANISM OF ACTION OF LEVODOPA IN PARKINSONISM
344 G. LEVODOPA PREPARATIONS 348 I. DECARBOXYLASE INHIBITORS 348 II.
SUSTAINED-RELEASE FORMS 352 III. ENHANCED DELIVERY AND UPTAKE . 354 H.
THERAPEUTIC USES FOR LEVODOPA OTHER THAN PARKINSONISM . . . . 354 J.
CLINICAL ISSUES REGARDING INITIATION OF LEVODOPA THERAPY . . . . 355 I.
EARLY VERSUS DELAYED USE OF LEVODOPA 355 II. LOW DOSE LEVODOPA
REGIMENS 359 K. CLINICAL ISSUES REGARDING DRUG HOLIDAY 359 REFERENCES
361 CHAPTER 14 ADVERSE EFFECTS OF LEVODOPA IN PARKINSON S DISEASE S.FAHN
385 A. HISTORICAL ASPECTS OF ADVERSE EFFECTS 385 B. CLASSIFICATION,
PATHOPHYSIOLOGY, AND TREATMENT OF ADVERSE EFFECTS . 389 I. PERIPHERAL
ADVERSE EFFECTS .392 1. GASTROINTESTINAL SYMPTOMS 392 XX CONTENTS 2.
CARDIAC DYSRHYTHMIAS 393 3. MELANOMA 393 II. CENTRAL ADVERSE EFFECTS 393
1. DYSKINESIAS 393 A. CHOREA 393 A. PEAK-DOSE CHOREA . . .393 P.
DIPHASIC CHOREA 393 B. DYSTONIA 394 A. PEAK-DOSE DYSTONIA 394 P.
DIPHASIC DYSTONIA 394 Y. OFF DYSTONIA 394 C. MYOCLONUS 395 D.
SIMULTANEOUS DYSKINESIAS WITH PARKINSONISM . . . .395 2. TACHYKINESIA
WITH HYPOKINESIA 395 A. TACHYPHEMIA 395 B. RUNNING GAIT 396 3.
FLUCTUATIONS 396 A. WEARING-OFF 396 B. SUDDEN OFF 397 C. RANDOM
OFF 397 D. YO-YO-ING . 398 E. EPISODIC FAILURE TO RESPOND TO EACH DOSE
398 F. DELAYED ON 398 G. WEAK LEVODOPA RESPONSE AT END OF DAY 399 H.
RESPONSE VARIES IN RELATION TO MEALS 399 .4. FREEZING 399 5. MENTAL
CHANGES 400 6. LOSS OF EFFICACY 400 A. CAUSED BY PYRIDOXINE 400 B. WITH
CONTINUING TREATMENT 400 7. MISCELLANEOUS 401 A. ALTERED SLEEP-WAKE
CYCLE . . . . .401 B. HYPERSEXUALITY 401 C. AKATHISIA . 402 D. SWEATING
403 E. POSTURAL HYPOTENSION 403 F. RESPIRATORY DISTRESS 403 G. FALLING .
404 H. PAIN 404 J. INCREASED PARKINSONISM 404 K. NEUROLEPTIC MALIGNANT
SYNDROME 404 REFERENCES 405 CHAPTER 15 MONOAMINE OXIDASE INHIBITORS IN
PARKINSON S DISEASE M. SANDLER AND V. GLOVER. WITH 8 FIGURES 411
CONTENTS XXI A. INTRODUCTION 411 B. THE INHIBITION OF DOPAMINE OXIDATION
BY (-)-DEPRENYL 414 C. CELLULAR LOCALISATION OF MAO IN THE BRAIN 416 D.
SAFETY OF (-)-DEPRENYL * . 416 E. ASSESSMENT OF MAO INHIBITION IN VIVO .
. .418 F. DISTRIBUTION OF (-)-DEPRENYL IN BRAIN AND BODY 419 G.
METABOLISM OF (-)-DEPRENYL TO AMPHETAMINE 420 H. OTHER ACTIONS OF
(-)-DEPRENYL 421 J. MAOANDMPTP 422 K. POSTSCRIPT 423 REFERENCES 426
CHAPTER 16 CLINICAL ACTIONS OF L-DEPRENYL IN PARKINSON S DISEASE M.D.
YAHRANDH.KAUFMANN 433 A. INTRODUCTION 433 B. PHARMACOLOGY 434 C.
CLINICAL TRIALS 435 I. COMBINED USE OF DEPRENYL WITH LEVODOPA 435 II.
L-DEPRENYL AS MONOTHERAPY . 438 D. SUMMARY 438 REFERENCES 439 CHAPTER 17
UPDATE ON BROMOCRIPTINE IN PARKINSON S DISEASE A.N. LIEBERMAN AND
M.GOLDSTEIN. WITH 9 FIGURES 443 A. INTRODUCTION 443 B. SIDE EFFECTS OF
LEVODOPA . 444 C. MECHANISMS FOR DECLINE IN RESPONSE . . . * . 445 D.
TREATMENT OF RESPONSE FLUCTUATIONS: BROMOCRIPTINE . . . . . 446 E.
STUDIES OF BROMOCRIPTINE THERAPY 449 F. PHARMACOLOGY OF BROMOCRIPTINE
454 REFERENCES 456 CHAPTER 18 PERGOLIDE IN THE TREATMENT OF PARKINSON S
DISEASE C.H. MARKHAM AND S.G. DIAMOND. WITH 3 FIGURES 459 A. CHEMISTRY
AND PHARMACOLOGY 459 B. CLINICAL STUDIES 460 I. OPEN-LABEL STUDIES 460
II. DOUBLE-BLIND STUDIES 462 III. A LONG-TERM FOLLOW-UP STUDY 462 XXII
CONTENTS C. HOW TO ADMINISTER 465 D. SIDE EFFECTS 467 REFERENCES ; 468
CHAPTER 19 LISURIDE PHARMACOLOGY AND TREATMENT OF PARKINSON S DISEASE G.
GOPINATHAN, R. HOROWSKI AND I. SUCHY 471 A. CHEMISTRY 471 B. TOXICOLOGY
. 471 C. PHARMACOKINETICS 472 D. BIOCHEMISTRY AND PHARMACOLOGY 473 I.
RECEPTOR BINDING 473 II. BIOCHEMISTRY 475 III. PHARMACOLOGY 475 IV.
NEUROPHYSIOLOGY 478 E. CLINICAL APPLICATIONS 481 I. CLINICAL
PHARMACOLOGY 481 II. APPLICATIONS IN CLINICAL ENDOCRINOLOGY 482 F.
LISURIDE IN NEUROLOGICAL DISEASES 487 I. PARKINSON S DISEASE AND RELATED
DISORDERS 487 1. ORAL APPLICATION 488 2. PARENTERAL APPLICATION . 497 3.
SUBCUTANEOUS LISURIDE: CONTINUOUS DOPAMINERGIC STIMULATION 498 II. OTHER
MOTOR DISTURBANCES 499 III. MIGRAINE 500 G. CONCLUSION 501 REFERENCES
501 CHAPTER 20 DOMPERIDONE AND PARKINSON S DISEASE J.D.PARKES. WITH 1
FIGURE 515 A. INTRODUCTION 515 B. DOMPERIDONE 516 I. ANIMAL PHARMACOLOGY
516 II. PHARMACOKINETICS IN HUMANS 516 III. BEHAVIOURAL EFFECTS 517 IV.
EFFECT ON THE PHARMACOKINETIC BEHAVIOUR OF LEVODOPA . . .518 C. EFFECT
OF DOMPERIDONE ON LEVODOPA RESPONSE 519 I. THERAPEUTIC RESPONSE TO
LEVODOPA IN PARKINSONISM . . . .519 II. DOPAMINE AGONIST-INDUCED
SICKNESS 522 III. LEVODOPA-ASSOCIATED CARDIOVASCULAR PROBLEMS . . . . .
. 522 1. DOMPERIDONE- AND LEVODOPA-INDUCED HYPOTENSION . . . 522 2.
DOMPERIDONE AND CARDIAC DYSRHYTHMIAS .523 CONTENTS XXIII 3. DOMPERIDONE
AND CEREBRAL BLOOD FLOW . 523 IV. LEVODOPA-ASSOCIATED RESPIRATORY
PROBLEMS 523 D. COMPARISON OF DOMPERIDONE WITH METOCLOPRAMIDE AND OTHER
NEUROLEPTICS IN THE MANAGEMENT OF PARKINSON S DISEASE . .525 E.
COMPARISON OF DOMPERIDONE WITH DECARBOXYLASE INHIBITORS IN THE
MANAGEMENT OF PARKINSON S DISEASE 526 REFERENCES 527 CHAPTER 21 NEW
ROUTES OF ADMINISTRATION FOR ANTIPARKINSONIAN THERAPY J.A. OBESO AND
S.MSTAHL. WITH 2 FIGURES 531 A. INTRODUCTION 531 B. DELIVERY METHODS 532
I. ENTERAL ADMINISTRATION 532 II. INTRAVENOUS ADMINISTRATION 533 III.
SUBCUTANEOUS ADMINISTRATION 533 IV. TRANSCUTANEOUS ADMINISTRATION . . .
. .534 C. CLINICAL STUDIES .534 I. ENTERAL ROUTES 534 II. INTRAVENOUS
ADMINISTRATION 535 1. LEVODOPA 535 2. LISURIDE 536 3. APOMORPHINE . 537
III. SUBCUTANEOUS INFUSIONS 537 IV. TRANSDERMAL APPLICATION 539 D.
CONCLUSION 539 REFERENCES 539 CHAPTER 22 TREATMENT OF PARKINSONIAN
FEATURES IN NEUROLOGICAL DISORDERS OTHER THAN PARKINSON S DISEASE R.F.
PEPPARD AND D.B. CALNE 543 A. INTRODUCTION 543 B. DRUG-INDUCED
PARKINSONISM . . . 543 C. WILSON S DISEASE . 547 D. MULTIPLE SYSTEM
DEGENERATIONS 549 I. STRIATONIGRAL DEGENERATION 549 II.
OLIVOPONTOCEREBELLAR ATROPHY 549 III. SHY-DRAGER SYNDROME 550 IV.
PROGRESSIVE SUPRANUCLEAR PALSY 550 V. SENILE PARKINSONISM 551 VI. THE
ALS-PARKINSON-DEMENTIA COMPLEX OF GUAM . . . . 551 VII. JOSEPH DISEASE
551 XXIV CONTENTS E. OTHER TYPES OF PARKINSONISM 551 I. POSTENCEPHALITIC
PARKINSONISM 551 II. PARKINSONISM DUE TO TOXINS 552 III.
HYPOPARATHYROIDISM 552 IV. HUNTINGTON S DISEASE . 552 F. CONCLUSIONS 552
REFERENCES 552 CHAPTER 23 MANAGEMENT OF PSYCHIATRIC SYMPTOMS IN
PARKINSON S DISEASE H.L. KLAWANS AND CM. TANNER 557 A. INTRODUCTION 557
B. DEPRESSION 557 C. PSYCHOSIS AND RELATED DISORDERS 560 I. EARLY ONSET
PSYCHOSIS 560 II. LATE ONSET PSYCHOSIS 561 D. DRUG-INDUCED HALLUCINATORY
SYNDROMES 564 I. ANTICHOLINERGIC DELIRIUM 564 II. HALLUCINATIONS WITH A
CLEAR SENSORIUM 565 E. TREATMENT OF PSYCHOSIS . . 566 F. ABERRANT SEXUAL
BEHAVIOR 568 REFERENCES 568 CHAPTER 24 INTRACRANIAL GRAFTS FOR THE
TREATMENT OF PARKINSON S DISEASE A.FINE AND H. A. ROBERTSON 573 A.
INTRODUCTION 573 B. SOURCES OF DOPAMINE-SECRETING CELLS 574 C. NEURAL
AND ADRENAL GRAFTS IN ANIMAL MODELS OF PARKINSON S DISEASE 575 I.
STUDIES IN THE RAT 576 II. STUDIES IN PRIMATES .578 D. DOPAMINERGIC
GRAFTS IN HUMANS 580 E. CONCLUSIONS 583 REFERENCES 583
|
| any_adam_object | 1 |
| author_GND | (DE-588)128984481 |
| building | Verbundindex |
| bvnumber | BV001779719 |
| callnumber-first | Q - Science |
| callnumber-label | QP905 |
| callnumber-raw | QP905 RC382 |
| callnumber-search | QP905 RC382 |
| callnumber-sort | QP 3905 |
| callnumber-subject | QP - Physiology |
| classification_rvk | XI 1701 XI 5700 |
| classification_tum | MED 604b MED 970b |
| ctrlnum | (OCoLC)18557026 (DE-599)BVBBV001779719 |
| dewey-full | 616.8/33061 615/.1 616.833061 615.1 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases 615 - Pharmacology and therapeutics |
| dewey-raw | 616.8/33061 615/.1 616.833061 615.1 |
| dewey-search | 616.8/33061 615/.1 616.833061 615.1 |
| dewey-sort | 3616.8 533061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02824nam a2200745 cb4500</leader><controlfield tag="001">BV001779719</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20140402 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">890804s1989 ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3540500413</subfield><subfield code="9">3-540-50041-3</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0387500413</subfield><subfield code="9">0-387-50041-3</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)18557026</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV001779719</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield><subfield code="a">DE-12</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-188</subfield><subfield code="a">DE-578</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QP905</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC382</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.8/33061</subfield><subfield code="2">19</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.1</subfield><subfield code="2">19</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.833061</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.1</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 1701</subfield><subfield code="0">(DE-625)152977:12907</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 5700</subfield><subfield code="0">(DE-625)153017:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">MED 604b</subfield><subfield code="2">stub</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">QV 4</subfield><subfield code="2">nlm</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">MED 970b</subfield><subfield code="2">stub</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Drugs for the treatment of Parkinson's disease</subfield><subfield code="c">contributors R. D. G. Blair ... Ed. Donald B. Calne</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin [u.a.]</subfield><subfield code="b">Springer</subfield><subfield code="c">1989</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXIV, 599 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Handbook of experimental pharmacology</subfield><subfield code="v">88</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Literaturangaben</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug Therapy</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Paralysis</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chemotherapy</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antiparkinsoniens</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Farmacotherapie</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Parkinson, Maladie de - Chimiothérapie</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ziekte van Parkinson</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antiparkinson Agents</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antiparkinsonian agents</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Parkinson Disease</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Parkinson's disease</subfield><subfield code="x">Chemotherapy</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakologie</subfield><subfield code="0">(DE-588)4045687-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Antiparkinsonmittel</subfield><subfield code="0">(DE-588)4224119-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Parkinson-Krankheit</subfield><subfield code="0">(DE-588)4044683-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Parkinsonismus</subfield><subfield code="0">(DE-588)4173363-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Parkinsonismus</subfield><subfield code="0">(DE-588)4173363-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Antiparkinsonmittel</subfield><subfield code="0">(DE-588)4224119-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Parkinson-Krankheit</subfield><subfield code="0">(DE-588)4044683-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="1"><subfield code="a">Pharmakologie</subfield><subfield code="0">(DE-588)4045687-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Calne, Donald B.</subfield><subfield code="d">1936-</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)128984481</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Blair, R. D. G.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Handbook of experimental pharmacology</subfield><subfield code="v">88</subfield><subfield code="w">(DE-604)BV002390716</subfield><subfield code="9">88</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=001199523&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-001199523</subfield></datafield></record></collection> |
| id | DE-604.BV001779719 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T15:35:52Z |
| institution | BVB |
| isbn | 3540500413 0387500413 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-001199523 |
| oclc_num | 18557026 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM DE-12 DE-355 DE-BY-UBR DE-29 DE-20 DE-188 DE-578 |
| owner_facet | DE-19 DE-BY-UBM DE-12 DE-355 DE-BY-UBR DE-29 DE-20 DE-188 DE-578 |
| physical | XXIV, 599 S. Ill., graph. Darst. |
| publishDate | 1989 |
| publishDateSearch | 1989 |
| publishDateSort | 1989 |
| publisher | Springer |
| record_format | marc |
| series | Handbook of experimental pharmacology |
| series2 | Handbook of experimental pharmacology |
| spelling | Drugs for the treatment of Parkinson's disease contributors R. D. G. Blair ... Ed. Donald B. Calne Berlin [u.a.] Springer 1989 XXIV, 599 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Handbook of experimental pharmacology 88 Literaturangaben Drug Therapy cabt Paralysis cabt Chemotherapy cabt Antiparkinsoniens Farmacotherapie gtt Parkinson, Maladie de - Chimiothérapie Ziekte van Parkinson gtt Antiparkinson Agents therapeutic use Antiparkinsonian agents Parkinson Disease drug therapy Parkinson's disease Chemotherapy Pharmakologie (DE-588)4045687-0 gnd rswk-swf Antiparkinsonmittel (DE-588)4224119-4 gnd rswk-swf Parkinson-Krankheit (DE-588)4044683-9 gnd rswk-swf Pharmakotherapie (DE-588)4076066-2 gnd rswk-swf Parkinsonismus (DE-588)4173363-0 gnd rswk-swf Parkinsonismus (DE-588)4173363-0 s Pharmakotherapie (DE-588)4076066-2 s DE-604 Antiparkinsonmittel (DE-588)4224119-4 s Parkinson-Krankheit (DE-588)4044683-9 s Pharmakologie (DE-588)4045687-0 s Calne, Donald B. 1936- Sonstige (DE-588)128984481 oth Blair, R. D. G. Sonstige oth Handbook of experimental pharmacology 88 (DE-604)BV002390716 88 GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=001199523&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Drugs for the treatment of Parkinson's disease Handbook of experimental pharmacology Drug Therapy cabt Paralysis cabt Chemotherapy cabt Antiparkinsoniens Farmacotherapie gtt Parkinson, Maladie de - Chimiothérapie Ziekte van Parkinson gtt Antiparkinson Agents therapeutic use Antiparkinsonian agents Parkinson Disease drug therapy Parkinson's disease Chemotherapy Pharmakologie (DE-588)4045687-0 gnd Antiparkinsonmittel (DE-588)4224119-4 gnd Parkinson-Krankheit (DE-588)4044683-9 gnd Pharmakotherapie (DE-588)4076066-2 gnd Parkinsonismus (DE-588)4173363-0 gnd |
| subject_GND | (DE-588)4045687-0 (DE-588)4224119-4 (DE-588)4044683-9 (DE-588)4076066-2 (DE-588)4173363-0 |
| title | Drugs for the treatment of Parkinson's disease |
| title_auth | Drugs for the treatment of Parkinson's disease |
| title_exact_search | Drugs for the treatment of Parkinson's disease |
| title_full | Drugs for the treatment of Parkinson's disease contributors R. D. G. Blair ... Ed. Donald B. Calne |
| title_fullStr | Drugs for the treatment of Parkinson's disease contributors R. D. G. Blair ... Ed. Donald B. Calne |
| title_full_unstemmed | Drugs for the treatment of Parkinson's disease contributors R. D. G. Blair ... Ed. Donald B. Calne |
| title_short | Drugs for the treatment of Parkinson's disease |
| title_sort | drugs for the treatment of parkinson s disease |
| topic | Drug Therapy cabt Paralysis cabt Chemotherapy cabt Antiparkinsoniens Farmacotherapie gtt Parkinson, Maladie de - Chimiothérapie Ziekte van Parkinson gtt Antiparkinson Agents therapeutic use Antiparkinsonian agents Parkinson Disease drug therapy Parkinson's disease Chemotherapy Pharmakologie (DE-588)4045687-0 gnd Antiparkinsonmittel (DE-588)4224119-4 gnd Parkinson-Krankheit (DE-588)4044683-9 gnd Pharmakotherapie (DE-588)4076066-2 gnd Parkinsonismus (DE-588)4173363-0 gnd |
| topic_facet | Drug Therapy Paralysis Chemotherapy Antiparkinsoniens Farmacotherapie Parkinson, Maladie de - Chimiothérapie Ziekte van Parkinson Antiparkinson Agents therapeutic use Antiparkinsonian agents Parkinson Disease drug therapy Parkinson's disease Chemotherapy Pharmakologie Antiparkinsonmittel Parkinson-Krankheit Pharmakotherapie Parkinsonismus |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=001199523&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV002390716 |
| work_keys_str_mv | AT calnedonaldb drugsforthetreatmentofparkinsonsdisease AT blairrdg drugsforthetreatmentofparkinsonsdisease |